EVO - Evotec SE ADR logo

Evotec SE ADR

EVO

Evotec SE is a drug discovery and development company that partners with pharmaceutical and biotechnology firms to create innovative therapeutics across multiple areas, including oncology, immunology, and metabolic diseases, serving both clinical and research needs.

βš•οΈ Healthcare NASDAQ Listed 2009 € EUR
$1,000 invested 20 years ago β†’$413today

Score Overview

1 Year
Score
Net Growth-97.00%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth-1.27%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score3.6
Net Growth-190.89%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth20.97%
Rev Trend60%
Revenue Consistencyβ€”
10 Years
Score
Net Growth-7x
Net Trend40%
Net Income Consistency
Rev Growth354.46%
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth-330.54%
Net Trend53%
Net Income Consistency
Rev Growth17x
Rev Trend82%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Evotec SE ADR has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • EVO

2020: 26.8% Β· 2021: 37.8% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 1.54β€”
1 Year2025-10-22
$ 3.93-60.81%
5 Years2021-10-22
$ 25.72-94.01%
10 Years2016-10-21
$ 2.25-31.51%
20 Years2006-10-20
$ 3.73-58.72%
All Time2009-12-04
$ 0.8678.22%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in EUR

Year
TTM€ 747M-€ 195M€ 445M
2025€ 757M-€ 99M€ 476M
2024€ 796M-€ 196M€ 396M
2023€ 781M-€ 83M€ 604M
2022€ 751M-€ 175M€ 707M
2021€ 618M€ 215M€ 858M
2020€ 500M€ 6M€ 589M
2019€ 446M€ 38M€ 359M
2018€ 375M€ 84M€ 149M
2017€ 257M€ 24M€ 101M
2016€ 164M€ 27M€ 127M
2015€ 127M€ 16M€ 134M
2014€ 89M-€ 6M€ 89M
2013€ 85M-€ 25M€ 98M
2012€ 87M€ 2M€ 65M
2011€ 80M€ 6M€ 63M
2010€ 55M€ 3M€ 68M
IPO2009€ 42M-€ 45M€ 58M
EVO - Evotec SE ADR logo

Evotec SE ADR fundamental performance

Between 2015 and 2025, revenue grew from € 127M to € 757M and net income went from € 16M to -€ 99M. Revenue increased in 8 of those 10 years; net income in 4.

Across Evotec SE ADR's full reported history, from 2009 to 2025, revenue grew from € 42M to € 757M and net income went from -€ 45M to -€ 99M. Revenue increased in 82% of the years measured; net income in 53%.

Evotec SE ADR currently holds a 5-year HDB Score of 3.6 out of 10. How the HDB Score is calculated.

Membership

Continue EVO’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies